Therapeutics Acquisition Corp. (RACA)

Amalgamated Bank raised its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 8.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,027 shares of the biotechnology company’s stock after acquiring an additional 809 shares during the period. Amalgamated Bank’s holdings in Cerevel Therapeutics were worth $425,000 as of its most recent SEC filing. A number of other hedge funds also recently modified their holdings of the company. Graham Capital Management L.P. raised its stake in shares of Cerevel Therapeutics by 304.6% in the third quarter. Graham Capital Management L.P. now owns 41,850 shares of the biotechnology company’s stock valued at $914,000 after purchasing an additional 31,506 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Cerevel Therapeutics in the 3rd quarter valued at $1,092,000. Calamos Advisors LLC bought a new position in shares of Cerevel Therapeutics during the 4th quarter worth about $12,945,000. Charles Schwab Investment Management Inc. boosted its position in shares of Cerevel Therapeutics by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 517,244 shares of the biotechnology company’s stock valued at $11,291,000 after acquiring an additional 15,261 shares in the last quarter. Finally, Citigroup Inc. increased its stake in Cerevel Therapeutics by 22.7% in the third quarter. Citigroup Inc. now owns 83,786 shares of the biotechnology company’s stock valued at $1,829,000 after acquiring an additional 15,507 shares during the period. Institutional investors own 87.73% of the company’s stock. Insider Buying and Selling at Cerevel Therapeutics In other news, Director N Anthony Coles sold 50,000 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $41.01, for a total transaction of $2,050,500.00. Following the sale, the director now owns 15,638 shares in the company, valued at $641,314.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 150,000 shares of company stock worth $6,213,500. 5.10% of the stock is currently owned by insiders. Cerevel Therapeutics Price Performance Shares of CERE opened at $42.10 on Monday. Cerevel Therapeutics Holdings, Inc. has a one year low of $19.59 and a one year high of $43.59. The business’s 50 day simple moving average is $42.20 and its 200-day simple moving average is $39.21. The company has a debt-to-equity ratio of 0.60, a current ratio of 10.22 and a quick ratio of 10.22. Analyst Upgrades and Downgrades Separately, Mizuho lifted their price objective on Cerevel Therapeutics from $25.00 to $45.00 and gave the company a “neutral” rating in a report on Friday, February 16th. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Cerevel Therapeutics has an average rating of “Hold” and a consensus price target of $42.67. Get Our Latest Report on CERE Cerevel Therapeutics Company Profile (Free Report) Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Equities research analysts at HC Wainwright reduced their Q2 2024 earnings per share estimates for shares of TransCode Therapeutics in a research report issued on Thursday, May 16th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.58) per share for the quarter, down from their previous estimate of ($0.50). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($1.98) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($1.98) EPS, FY2026 earnings at ($0.47) EPS and FY2028 earnings at ($0.39) EPS. TransCode Therapeutics Stock Performance TransCode Therapeutics stock opened at $1.15 on Monday. TransCode Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $309.60. The company has a market capitalization of $7.61 million, a P/E ratio of 0.00 and a beta of -0.36. The stock has a 50-day simple moving average of $0.70 and a 200-day simple moving average of $3.73. Institutional Trading of TransCode Therapeutics A hedge fund recently raised its stake in TransCode Therapeutics stock. Sabby Management LLC raised its stake in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) by 32.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 250,309 shares of the company’s stock after acquiring an additional 61,872 shares during the period. Sabby Management LLC owned approximately 12.33% of TransCode Therapeutics worth $126,000 as of its most recent SEC filing. About TransCode Therapeutics (Get Free Report) TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Read More Five stocks we like better than TransCode Therapeutics Bank Stocks – Best Bank Stocks to Invest In MarketBeat Week in Review – 5/13 – 5/17 How to Use the MarketBeat Dividend Calculator Take-Two Interactive Software Offers 2nd Chance for Investors The Top 3 Healthcare Dividend Stocks to Buy and Hold Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook

Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”

BOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, a Delaware corporation (“the Company”) (Nasdaq: RACA) announced today that its registration statement on Form S-4 (File Number 333-254600) (as amended, the “Registration Statement”), relating to the previously announced business combination (the “Business Combination”) with POINT Biopharma Inc. (“POINT”), has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) and that it will com

INDIANAPOLIS--(BUSINESS WIRE)--POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company's investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer (mCRPC) who are not eligible for

INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company's investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer (mCRPC) who are not eligible for chemotherapy.